Indeed, MCL1 inhibition is currently in early clinical testing for multiple myeloma and MYC positive diffuse large B-cell lymphoma (DLBCL) with promising results (Clinicaltrails.gov, NCT02992483). The gene discussed is MYC; the disease is AL amyloidosis.